Amyloid-beta clearance in Alzheimer's disease (Record no. 76547)

MARC details
000 -LEADER
fixed length control field 02051naaaa2200325uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/40785
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220220084126.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 978-2-88919-443-8
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9782889194438
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3389/978-2-88919-443-8
Terms of availability doi
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Robert Marr
Relationship auth
245 10 - TITLE STATEMENT
Title Amyloid-beta clearance in Alzheimer's disease
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Frontiers Media SA
Date of publication, distribution, etc. 2015
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (111 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc. Strong evidence continues to accumulate indicating that amyloid-beta (Aß) is a central part of Alzheimer’s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aß are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to Aß clearance in AD. The topics covered include proteases that degrade Aß and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
Use and reproduction rights https://creativecommons.org/licenses/by/4.0/
Source of term cc
-- https://creativecommons.org/licenses/by/4.0/
546 ## - LANGUAGE NOTE
Language note English
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term amyloid-beta
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Signal Transduction
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Proteases
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term LDL receptors
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Clearance
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Alzheimer's disease
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Eliezer Masliah
Relationship auth
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="http://journal.frontiersin.org/researchtopic/2235/amyloid-beta-clearance-in-alzheimers-disease">http://journal.frontiersin.org/researchtopic/2235/amyloid-beta-clearance-in-alzheimers-disease</a>
Access status 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/40785">https://directory.doabooks.org/handle/20.500.12854/40785</a>
Access status 0
Public note DOAB: description of the publication

No items available.